Source comparison
BPC-157 Research Geriatric Considerations: Research Model Comparison
Young Adult Rodent (3–6 months) 10–50 mcg/kg daily None required 4.0–4.5 hours Tissue repair velocity Baseline reference model. Standard pharmacokinetics apply Aged Rodent (18–24 months) 8–40 mcg/kg every 36 hours Reduce starting dose 15–20%, extend interval 5
This comparison does not assign a generated winner or score.
- Young Adult Rodent (3–6 months)
- 10–50 mcg/kg daily
- None required
- 4.0–4.5 hours
- Tissue repair velocity
- Baseline reference model. Standard pharmacokinetics apply
- Aged Rodent (18–24 months)
- 8–40 mcg/kg every 36 hours
- Reduce starting dose 15–20%, extend interval
- 5.5–6.0 hours
- Receptor saturation markers (VEGF plateau)
- Requires dose individualization. Extended half-life narrows therapeutic window
- Polypharmacy Model (NSAID pretreatment)
- 10–30 mcg/kg daily
- 48-hour NSAID washout recommended
- 4.8–5.2 hours
- COX-2 expression, healing velocity
- NSAID co-administration slows angiogenic response without blocking efficacy entirely
- Anticoagulant Model (warfarin co-treatment)
- 10–40 mcg/kg daily
- No dose adjustment required
- 4.5–5.0 hours
- INR, bleeding time
- No clinically significant coagulation alterations observed at therapeutic doses